Fundraising FoxAMR Action Fund — 2020 Investments
2 investments dated 2020 · listed companies and verified rows first · show all
Rgenta develops orally available small molecule therapies that target RNA to address diseases previously considered undruggable, with programs in oncology (targeting proteins such as MYB in solid tumors and hematologic cancers) and central nervous system repeat expansion disorders like Huntington's disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Travis Wager(Co-founder, President and CSO)inHualin Simon Xi(Executive Officer, Director)Zhiping Weng(Co-founder)inSimon Xi(Co-founder and CEO)inJackie Walling(CMO)Debasish Roychowdhury(Director)
Board seatMartin Heidecker· per SEC Form D
Co-investorsDelos CapitalVivo CapitalBoehringer Ingelheim Venture FundKorea Investment PartnersLilly Asia VenturesMatrix Capital Management+1 more
Libra Therapeutics develops small molecule therapeutics targeting lysosomal function and autophagy to treat neurodegenerative diseases including ALS, Parkinson's, Alzheimer's, and Huntington's disease.
BiotechLongevityMedical Devices
Dr. Gill(Chief Scientific Officer)
Co-investorsDolby Family VenturesEpidarex CapitalBoehringer Ingelheim Venture Fund
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.